Trial Profile
A Phase II Clinical Study to Evaluate the Efficacy and Safety of GB226 for the Treatment of Chinese Population With Relapsed and Refractory Peripheral T Cell Lymphoma (PTCL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Geptanolimab (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Genor Biopharma
- 02 Mar 2021 Planned End Date changed from 30 Dec 2020 to 30 Dec 2022.
- 02 Mar 2021 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.
- 20 Jun 2020 Planned number of patients changed from 97 to 86.